Pluri Inc. · NASDAQ:PLUR
Pluri — Investor Presentation (January 2026)
27 slides from Pluri's investor presentation, January 2026
Slide 1: Where Technology Comes to Life
WHERE TECHNOLOGY COMES TO LIFE Q1 2026
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements within the Israeli Securities Law, 1968, the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended, regarding Pluri Inc. and/or its subsidiaries (collectively the “Company” o
Slide 3: Pluri Venture Creation
Pluri Venture Creation Company Sectors Partners Regenerative Medicine ~$17 million (as of and wellness June 30, 2025) Cultivated Meat ~ Contract Development and Manufacturing Organization Cell-Based Agriculture
Slide 4: Eight Billion Lives. One Planet. Zero Time to Waste.
Eight Billion Lives. One Planet. Zero Time to Waste. Aging and Health Climate Change Food Security Sustainability A growing, aging world urgently needs scalable, sustainable solutions
Slide 5: Pluri Technological Platform
Pluri Technological Platform Innovative Validated
Slide 6: Bio-Farming: Industrial Scale Production
Bio-Farming: Industrial Scale Production PluriMatrix
Slide 7: Spreading Risks Across Multiple Verticals
Spreading Risks Across Multiple Verticals Cultivated coffee Medical aesthetics & wellness 100% ownership 100% ownership Cultivated cacao Acute Radiation Syndrome 79% ownership • $2.2M funded by U.S. gov • Hemafund collab- advancing availability in Ukraine Cell-based agriculture • Funded POC with ICL
Slide 8: Partnership that Becomes Independence: a Proven Path to Value Creation
Partnership that Becomes Independence: a Proven Path to Value Creation Pluri holds majority ownership in all companies in which it is a partner
Slide 9: Growing the Future of Food with Cultivated Meat
Growing the Future of Food with Cultivated Meat Ever After Foods leverages Pluri’s cell expansion technology to produce mass scale, cost-effective food products in an efficient and sustainable manner, aiming to solve the industry’s scalability challenges Environmental Ethical Consumer ● Less land an
Slide 10: Ever After Foods Milestones
Ever After Foods Milestones Expected completion of manufacturing system development, initiation of regulatory processes, and receipt of initial regulatory approvals in selected markets • Tnuva $7.5 million according to a $40 million pre- money valuation • Pluri granted exclusive global royalty-beari
Slide 11: Reimagining Coffee Without Ecological Cost
Reimagining Coffee Without Ecological Cost Climate Change Land Shortage decrease reduce Price Instability Carbon Footprint risen water
Slide 12: Designing production scale system (Production N system)
Designing production scale system (Production N system) Purpose System design Expected output Designing system with 10,000 L chambers and Up to 84,000kg wet or 10,000 PluriMatrix up to 7 chambers in 10,000kg dry chambers for plant cell parallel growth (N system)
Slide 13: The Coffeesai Solution uses 100% Real Coffee
The Coffeesai Solution uses 100% Real Coffee Drying Roasting Brewing
Slide 14: A Consistent Methodology for Rapid, De-risked Venture Creation
A Consistent Methodology for Rapid, De-risked Venture Creation
Slide 15: Cacao at risk due to climate change
Cacao at risk due to climate change Unstable supply Rising prices $11,000 Complex supply chain Cocoa market growth Inconsistent quality $13.5
Slide 16: Kokomodo's achievements
Kokomodo’s achievements • Stable and scalable 14 cacao cell lines • Health-promoting antioxidants and high nutrition values • Flavor and aroma profiles • Scaling up from lab-scale to semi- industrial production with proven POC
Slide 17: Kokomodo Milestones
Kokomodo Milestones kokomodo Cultivating Cocoa’s Future Feb. May H2 2026 2024 2025 2025 Company founded by Plantae Completion of acquisition POC deals with Completion of development Bioscience, The Kitchen (a by Pluri global partners processes to scale up Strauss Group company), and Tal Govrin. An i
Slide 18: Health and Wellbeing
Health and Wellbeing
Slide 19: Revolutionizing Beauty and Wellness Through Cell Science
Revolutionizing Beauty and Wellness Through Cell Science Market Science-Driven Opportunity Innovation $200B From Therapy to Partnership & Lifestyle Growth
Slide 20: Stem Cell Use Authorization in the US
Stem Cell Use Authorization in the US Premium Aesthetics Solutions The U.S. Food and Drug Administration (FDA) has authorized Mayo Clinic to offer mesenchymal stem cells as part of the Regenerative Nephrology Compassionate Use Program.
Slide 21: Leveraging CDMO Capabilities to Create Revenue and Value
Leveraging CDMO Capabilities to Create Revenue and Value
Slide 22: Pluri's Contract Development Manufacturing Organization
Pluri’s Contract Development Manufacturing Organization With more than 15 years of GMP manufacturing expertise, Pluri is leveraging its skilled team, 47,000 sq ft facility and logistics capabilities for cell therapy CDMO clients GMP Certified Facility Overview ● Facility compliant to Europe, ● Produ
Slide 23: PLX-R18 for Acute Radiation Syndrome
PLX-R18 for Acute Radiation Syndrome Studies and Collaborations Survival Rate • The U.S. National Institutes of Health (NIH) and the Department of Defense (DoD) funded $2.2 million out of the total $4.2 million budget Significant increase (68%) vs placebo (p<0.0001)* originally allocated for the stu
Slide 24: Our Collaborative Network of Partnerships
Our Collaborative Network of Partnerships Regulatory Scientific Collaborations Funding and Partnering
Slide 25: Key Milestones for 2026
Key Milestones for 2026 Medical aesthetics and placental cells: Achieving significant milestones with existing Accelerating product commercialization in the US strategic partners, expanding collaborations with and Europe, starting significant sales and first additional partners, and regulatory filin
Slide 26: Our Team
Our Team Yaky Yanay Liat Zalts Lior Raviv Dr. Michal Sheleg, PhD Nimrod Bar Zvi CEO & President Chief Financial Officer Chief Technology Officer VP Clinical Development Chief Commercial Officer Dr. Arthur Machlenkin, PhD Nofar Glaich-Dabach Orly Amiran Efrat Kaduri Ori Shalem Chief Scientific Office
Slide 27: Thank You
THANK YOU. Our cell-based innovations are aimed at transforming industries with a goal to create a more sustainable, healthier world. From the food we eat to the medicine we consume, we are building solutions that can potentially serve humanity, one breakthrough at a time. For further info: investor